This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


ARTham Therapeutics, Inc
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2020/7/29
Profile

Delegates :
Hiroshi Nagabukuro


Incorporated :
July  1 , 2018

Paid in Capital :
 Million yen  

Employees :
6 人

Address :
24-8, Yamashita-cho, Naka-ku, Yokohama Kanagawa Japan
〒231-0023

TEL/FAX :
+81-45-225-8858 / +81-45-225-8858

URL:
https://www.arthamther.com/en/

Attachment :

Mission/Background :
Deliver “medicines that matter” to improve patient health and contribute to enhanced quality of life. At ARTham Therapeutics, we will create value by developing innovative medicines that are disease modifying and improve patient health.

Technology & Business
ARTham Therapeutics Inc., is a clinical stage biopharmaceutical company that will deliver ‘medicines that matter’ for patients. Our goal is to create innovative medicines that are disease modifying and satisfy significant unmet medical need. To deliver on cost and time efficiency, ARTham will run a virtual R&D operating model that seeks innovation through the best academic and business partners.
Products & Service
Products & Service Name
Stage
Outline
Milestone
ART-648
Phase1
First PDE4 inhibitor candidate for effective treatment of inflammatory skin diseases
Ph-2 POC clinical trial
ART-001
Phase1
First in Class PI3K inhibitor for the treatment of vascular malformations and overgrowth syndromes
Ph-2 POC clinical trial












Highlights
1. Running a Ph-1 clinical trial of ART-648
2. Presented the preclinical data of ART-648 at International Liver Congress 2019
3. ART-648 has received a grant from AMED, Japanese Agency for Medical Research and Development (2020-2022)

4. Preparing a Ph-1 clinical trial of ART-001
5. ART-001 has received a grant from AMED, Japanese Agency for Medical Research and Development (2018-2020)
Hot news

Alliance strategy
1. licensing OUT ARTham clinical program
2. Licensing IN new program(s), Discontinued program in pharmacos due to a business reason is high priority
3. Seeking CROs and/or CDMOs having excellent capability


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.